Metformin: An AMPK-dependent antidiabetic drug with novel medical applications

Maysa Ahmed Mobasher
Welcome letter from Editor-in-Chief

Welcome to the Int J Cancer and Biomedical Research (IJCBR)!

It is with great pleasure that I write this editorial to welcome you to the IJCBR. This journal provides a platform for publication of original and reviews research articles, short communications, letter to editor, thesis abstract, conference report, and case studies. These types of publication are directed at the interface of the fields of cancer and biomedical research.

The IJCBR relies on a distinguished expert of the Advisory and Editorial Board Members from the top international league covering in depth the related topics. They timely review all manuscripts and maintain highest standards of quality and scientific methodology and ethical concepts. Meanwhile, we take all possible means to keep the time of the publication process as short as possible.

I take this chance to welcome your contributions to the IJCBR and have every expectation that it will soon become one of the most respected journals in both the fields of cancer and biomedical research.

Mohamed L. Salem,
Editor in Chief
Metformin: An AMPK-dependent antidiabetic drug with novel medical applications

Maysa Ahmed Mobasher
Department of Pathology, College of Medicine, Jouf University, Saudi Arabia
Department of Clinical Pathology, El Ahrar Educational Hospital, Ministry of Health, Zagazig, Egypt

ABSTRACT
Metformin (MET) is a well-known antidiabetic drug for type 2 diabetes mellitus (T2DM) treatment. The therapeutic effects of MET come from its ability to decrease both the production of hepatic glucose and its absorption via the intestine and improve insulin hormone sensitivity. This review aims to summarize the new medical applications of this old antidiabetic drug. Nowadays, MET is used in pre-clinical trials to treat cancer and slow the proliferation rate, emerging from its hypoglycemic effect and antioxidant activity. MET enhanced the functions of immune T-cells and reduced the proinflammatory mediators in macrophages. Moreover, based on the pre-clinical studies, its effect on the reproductive system is confirmed as MET showed an excellent candidate for polycystic ovary syndrome (PCOS) treatment and improved ovarian cyclicity, and reduces gestational diabetes risks in female; however, the effect on sperm number and motility is still in debate. Treatment with MET also showed some beneficial effects on bone health, and its administration led to a deficiency in vitamin B12. Furthermore, MET enhances anaerobic pathways and increases lactic acid levels. This review demonstrated the novel uses of MET in different clinical settings with explained mechanisms of action.

Keywords: Anticancer; antioxidant; anti-diabetic; obesity; Metformin.

INTRODUCTION
Metformin (MET) is a well-known anti-hyperglycemic agent for type 2 diabetes mellitus (T2DM) management, which was originated naturally from galegine found in Galega officinalis (Bailey and Day, 2004). MET has been used as glucose-lowering agents via reducing gluconeogenesis in hepatocytes, decreasing glucose absorption from the intestine, and restoring the body’s response to insulin in peripheral tissues (Viollet et al., 2012). MET is a unique antidiabetic drug not only because it does not cause severe hypoglycemia but also because it can improve protein synthesis. MET was discovered in 1922 (Werner and Bell, 1922). Between 1940-1957s, it was used in malaria, influenza, and adult-onset diabetes treatments. From 1995-1998s, MET was applied in clinical uses in the USA and UK to manage hyperglycemia in T2DM. In addition to its use as an antidiabetic drug, MET was recently used for another clinical setting, such as obesity treatment, anticancer, antioxidant, hepato-, and reno-protective (Scheen et al., 2015; Chukwunonso et al., 2016). Besides the previous MET uses, it can also be used simultaneously as a cardio-protective agent, augment the immune system, and increase probiotics’ efficiency (Nasri, 2013).

Mechanisms of Action of Metformin
MET is usually taken orally with a wide therapeutic dose range from 1,000 to 3,000 mg/day. About 70% of MET is absorbed approximately from the gastrointestinal tract to the body tissues through the bloodstream, the remaining passing into the colon then excreted in feces (Graham et al., 2011). The absorption of MET is mediated primarily by the plasma membrane monoamine transporter in the intestine. However, the organic cation transporters 1 and 3 may also contribute to the absorption process (Gong et al., 2012).
Previous studies showed that MET inhibits mitochondrial complex I, oxidative phosphorylation, ATP production, and energetic stress (Gheissari, 2013; Rena et al., 2017). In this regard, the metabolic shift by MET leads to the activation of 5’-adenosine monophosphate-activated protein kinase (AMPK), subsequently retrieves energy balance by switching off ATP-consuming anabolic mechanisms (Rena et al., 2017). Furthermore, MET enhances anaerobic pathways by inhibiting pyruvate dehydrogenase (PDH), glyceraldehyde dehydrogenase, and mitochondrial reducing agents. Inhibiting glyceraldehyde dehydrogenase by MET leads to a decrease in both lactate and glycerol metabolism, which in turn decreases glucose biosynthesis and increases lactic acid levels (Zoncu et al., 2011).

The mammalian target of rapamycin (mTOR) is a downstream target of AMPK involved in regulating energy homeostasis by modulating cellular processes, such as protein synthesis and autophagy implicated in cell proliferation and tumorigenesis in cancer (Madiraju et al., 2014). MET has been demonstrated to downregulate mTOR signaling through either AMPK-dependent or independent mechanisms (Kalender et al., 2011). As shown in Figure 1, MET can regulate other pathways, including the nuclear factor kappa B (NF-kB) (Chaudhary et al., 2012) and mitogen-activated protein kinase (MAPK)/c-Jun NH2-terminal kinase (JNK). Further, MET blocked the adenyl cyclase enzyme, which in turn inhibited glucagon-induced cAMP production.

**Metformin and Oxidative Stress**

MET showed antioxidant activity, suggesting its potentiality against several diseases (Esteghamati et al., 2013). Interestingly, decreasing insulin sensitivity is linked with low mitochondrial protein abundance and associated with reactive oxygen species (ROS) accumulation. Several studies have indicated that MET treatment led to decreased ROS cellularity, which protects against tissue injury (Rouhi and Ganji, 2013). The action of MET in reducing ROS generation might be due to the suppression of pro-oxidant enzyme systems like NADPH oxidase that cause superoxide anions production (Piwkowska et al., 2010). As a result of hyperglycemia in diabetic patients, a progressive accumulation of cellular ROS accompanied by advanced glycation end products (AGES) was significantly noticed. MET treatment has been found to suppress AGES by enhancing the antioxidant capacity (Chakraborty et al., 2011). A previous study indicated that MET ameliorated endoplasmic reticulum (ER) stress-induced by albumin in human proximal tubular cells by ROS-Src-kinase-mTOR pathway through suppression of ROS generation and augmentation of antioxidants status (Azimova et al., 2014). The antioxidant effects of MET could mediate through AMPK activation, which led to reducing ROS and inhibiting profibrotic/proinflammatory factors. In the liver tissue, a weak antioxidant defense system and oxidative stress led to the hepatic lesion. A recent study showed that co-treatment with MET and propolis attenuates hepatic lesions in DM rats (Nna et al., 2018).

**Metformin, Immunity, and Inflammation**

Due to the immune-modulatory features of MET, it may be used in future trials in the treatment of immune-mediated inflammatory diseases (Pollak, 2017; Schuiveling et al., 2018). MET led to the activation of AMPK downstream. Therefore, it influenced immune functions and homeostasis. Studies suggested that MET treatment may affect different acquired and innate immune cellularity (Schuiveling et al., 2018). MET exerts several actions on T helper 17/regulatory T cell (T-reg) balance, cytokine synthesis, macrophage polarization, autoantibodies production, neutrophils release, and extracellular matrix remodeling (Tomczynska et al., 2016). T cells’ differentiation and activation depending on the mTOR signaling via activation of the STAT transcription pathway (Saleiro and Platanias, 2015). In this regard, MET treatment can reduce adenovirus-induced acute liver injury partially mediated through the mTORC1 pathway in T lymphocytes in mice. It has also been reported that MET increases the number of T-reg cells in experimental autoimmune encephalomyelitis (EAE) through the inhibition of the mTOR pathway (Sun et al., 2016).
Similarly, the effect of MET on collagen antibody-induced rheumatoid arthritis has been addressed (Kang et al., 2013). Further studies have been evaluated the impact of MET on Th17-mediated inflammation, acute graft-versus-host, and colitis disease (Lee et al., 2015; Park et al., 2016). MET co-treatment with drospirenone/ethinylestradiol in polycystic ovary syndrome (PCOS) patients has been shown to decrease CD4+CD28null T cells frequency. It was reported that the MET antitumor action was mediated by AMPK activation in lymphoma (Shi et al., 2012). Furthermore, MET administration has been accompanied by an improvement in the response rate in diabetic diffuse large B-cell lymphoma patients and attenuate autoimmunity signs (Lee et al., 2017).

In vitro study showed that MET had anti-inflammatory properties and inhibited LPS-induced pro-IL-1β in murine bone marrow-derived macrophages (Jing et al., 2018). Moreover, MET treatment has been shown to inhibit collagen synthesis and fibrosis via the TGF-β/Smad3 signaling pathway in cardiac fibroblasts. A similar effect was observed in other cellular models, hepatic stellate cells and renal fibroblasts (Lu et al., 2015). Similarly, in the lungs, MET attenuates pulmonary fibrosis and reduced collagen accumulation. MET administration is linked with a decrease in the production of TGF-β, a well-established inducer of fibrosis (Li et al., 2015).

**Metformin and Obesity**

MET has been used to control overweight in diabetic patients (Wang et al., 2017). MET treatment interestingly showed decreased low-density lipoproteins (LDL-bad cholesterol) and triglycerides levels, which promotes weight loss in obese patients. It activates lipolysis by inhibiting adipogenesis and uncoupling proteins (Desprérs, 2003). Indirectly, MET inhibits carbohydrate absorption and bile salt uptake through stimulation of glucagon-like peptide-1 (GLP-1), which may inhibit food intake and energy production (Petersen et al., 2017). Treatment with MET is linked with an increase in fatty adiponectin that enhances fatty acid oxidation in T2DM patients (Nie and Li, 2017). In parallel, MET inhibits rapamycin's mammalian target (mTOR), which in turn mitigates insulin's pro-obesogenic activity (Kalender et al., 2011).

**Hepatoprotective Effect of Metformin**

MET might protect the liver against viral and chemical hepatotoxics via different mechanisms, including activation of AMPK and inhibition of mitochondrial NADH dehydrogenase complex I, MAPK, and Smads phosphorylation (Iranshahy et al., 2019). MET shifted the metabolic status in hepatocytes toward the inhibition of glucose, lipid, protein synthesis, and activation of fatty acids oxidation and glucose uptake (Rena et al., 2017). Recent studies reported that MET might also protect the liver cells from injury induced by toxic substances such as thioacetamide, alcohol, methotrexate, ac tinaminoph en, cisplatin, and arsenic trioxide (Borole et al., 2016; Saeedi Saravi et al., 2016; Mansour et al., 2017; Al-Hashem et al., 2018). Since the liver is the main organ to eliminate ac tinaminoph en (Mobasher and Valverde, 2014), MET successfully protected hepatocytes from acetaminophen toxicity via MAPK, non-MAPK, and inhibited JNK activation (Kim et al., 2015). MET prevented liver fibrosis and inflammation in CCl4 induced cirrhotic rats (Xu et al., 2016). Using Continuous treatment with MET in cirrhotic T2DM patients increased their survival rate. MET could have a beneficial impact in non-alcoholic fatty liver patients regardless of its effects as an insulin sensitizer (Mazza et al., 2011). The hepatoprotective effect of MET might be due to the enhancement of antioxidant responses by increasing glutathione reductase (GR), glutathione peroxidase (GPx), and cysteine synthase levels and upregulation of nuclear factor (Nrf2) and suppression of transforming growth factor-beta 1(TGF-β1) (Iranshahy et al., 2019).

**Metformin and Diabetes Mellitus Fighter**

MET is commonly used to treat T2DM patients and prediabetic patients (Ortega et al., 2014). Comparing to insulin and chlorpropamide therapy, MET showed advancement in controlling diabetes complications and mortality. Upon MET treatment, the Incidence of T2DM decreased by 34% (Nasri et al., 2013). Several mechanisms showed the ability of MET to reduce serum glucose levels in T2DM.
patients (Konopka et al., 2019). For instance, it improves insulin sensitivity via increasing peripheral glucose uptake and utilization. Besides, it also decreases hepatocytes' capability to produce glucose by reducing the rate of gluconeogenesis (Wiernsperger and Bailey, 1999) and glycogenolysis without induction of hypoglycemia. Although the molecular mechanism of metformin action has not been well described, some studies triggering activation of AMPK as the primary mechanism of protection (Shaw et al., 2005). However, other researchers have shown that AMPK is not involved. Furthermore, in muscle tissues, MET stimulates glucose transport and insulin signaling (Seo-Mayer et al., 2011). Clinical studies supported the capability of MET to reduce the incidence of myocardial infarction, angina, stroke, peripheral vascular disease, and sudden death in T2DM patients (Azimova et al., 2014; Kooy et al., 2009; Lamanna et al., 2011). Besides the previous actions of MET, it increases the peripheral glucose disposal that arises by increasing non-oxidative glucose disposal into skeletal muscle (Nasri et al., 2013).

The therapeutic and renoprotective efficacy of MET against nephrotoxicity was previously investigated by Rafieian-Kopaei and Nasri (2013), Baradaran (2012), and Eisenreich and Leppert (2017) (Rafieian-Kopaei and Nasri, 2013; Baradaran, 2012; Eisenreich and Leppert, 2017). Several studies have reported that MET could inhibit hyperglycemia on AMP-activate protein kinase (AMPK) signaling in kidney glomerular and tubular compartments. Furthermore, MET was able to ameliorate the renal injury induced by hyperglycemia (Takiyama et al., 2011; Lee et al., 2013). It has been reported that MET significantly decreases albuminuria in DM patients and protects against the podocytes, which could be a promising agent in diabetic nephropathy management (Nasri and Rafieian-Kopaei, 2013; Tavafi, 2013). Furthermore, MET protects against gentamicin-induced acute renal failure and after unilateral ischemia-reperfusion in rats (Amini et al., 2012). Taheri et al. (2012) reported that activation MET could prevent hypoxia and protects renal injury via inhibition of mitochondrial respiratory complex I (Taheri et al., 2012). MET has been shown to induce autophagy by phosphorylating key proteins ULK1, VPS34, and Beclin 1. These findings could encourage physicians to use MET in diabetic nephropathy control. Another study showed that MET might cause side effects on renal function in T2DM patients and moderate chronic kidney diseases due to lactate accumulation, which led to lactic acidosis (LA) (Hsu et al., 2017). Recently, a new study reported that MET could be applied safely in T2DM patients with chronic kidney diseases after optimizing its dose (MacCallum and Senior, 2019).

Figure 1. Metformin inhibitory and stimulatory effects.
**Metformin and Cardiovascular Health**

Pre-clinical and clinical studies showed that MET has a potential role in lowering cardiovascular complications in diabetic and non-diabetic patients (Luo et al., 2019). Diabetic patients are most likely subjected to risk factors of cardiovascular diseases (CVD) development due to the changes in the internal environment, which directly or indirectly affected heart functions. Controlling the hyperglycemia in diabetic patients is ultimate in CVD management (Avogaro et al., 2007). It has been reported that MET was also able to reduce atherosclerotic cardiovascular disease in T2DM patients (Charytanet et al., 2019). In the same line, previous studies suggest that MET exhibited antifibrotic effects with the potential impacts on cardiovascular disease (Lu et al., 2015; Shen et al., 2016). MET can reduce the myocardial infarction (MI) incidence in freshly diagnosed obese T2DM patients (Varjabedian et al., 2018).

Similarly, MET can potentially limit ischemia-reperfusion injury in MI animal models. Several studies have recently postulated that MET positively impacts a cardiovascular protecting agent (Younis et al., 2017; Charytan et al., 2019) because MET showed to reduce blood fats, body weight, and blood pressure (Van Stee et al., 2018). In a contradictory study, MET could be unsafe to use as a treatment for diabetic patients with cardiac shortage because it may increase the risk of LA (Inzucchi et al., 2014).

**Metformin and Reproductive Health**

The menstrual cycles and fertility might be improved by MET treatment. MET showed an excellent candidate for PCOS treatment and improved ovarian cyclicity, and reduces gestational diabetes risks (Brown et al., 2016; Vanlalhruaii et al., 2018). MET increased the pregnancy rates and decreased the ovarian hyperstimulation syndrome risk (Tso et al., 2015). MET reported regulating oocyte maturation. It is considered a promising contributor in the crosstalk between somatic cells and oocytes for the normal development of female germ cells and embryos. MET influences the cell cycle by altering the Follicle-stimulating hormone-induced proliferation and cyclin-dependent kinase inhibitor in the primary culture of mouse Sertoli cells (Riera et al., 2012). In obese patients, MET treatment improves sperm concentration and motility in the same way observed in obese rats (Morgante et al., 2011). MET can modulate and improve pituitary Luteinizing hormone (LH) and regulate Leydig cell steroidogenesis in testis. MET decreases sperm motility in pigs (Hurtado et al., 2012). In the rabbit, the MET treatment showed a negative effect on concentration, mobility, and the number of morphological abnormalities of spermatozoa (Naglaa et al., 2010). In birds, MET administration improved their sperm viability and mobility (Nguyen et al., 2014).

**Metformin and Cancer**

Cancer cells are characterized by their rapid proliferation; therefore, they use a huge amount of glucose (Jang et al., 2013). Depletion of glucose or reducing its amount from cancer cells is an excellent strategy to slow the cancer cells’ growth or inhibit their proliferation (Ryu et al., 2014). Several researchers around the world use MET as a promising candidate for cancer treatment (He et al., 2015; Saraei et al., 2019), and our research group is getting similar results in hepatocellular carcinoma (HCC) with pre-existing diabetes mellitus rats (Mobasher et al., 2020; Mobasher et al., 2021). Multiple scientific reports linked the presence of diabetes mellitus and cancer incidence (Wang et al., 2015). Hyperglycemia is a key factor for rapid cell proliferation and directly impacts carcinomas’ cell proliferation, apoptosis, and metastasis (Ryu et al., 2014). In this regard, diabetic patients are more susceptible to cancer than non-diabetics, and MET may help prevent tumor formation. In this line, reports have concluded that the treatment of diabetic patients with MET could decrease the risk of cancer development and progression as compared to those using other antidiabetic drugs (Libby et al., 2009). For instance, MET treatment protects against pancreatic cancer. MET inhibits renal cancer cell proliferation by down-regulating cyclin-D1, inducing G0/G1 cell cycle arrest, and upregulates AMPK activity along with mTOR pathway inhibition (Libby et al., 2009). MET also has destructive effects on osteosarcoma cancer stem-like cells, and potentially, it can reduce the risk of cancer in continuous use by T2DM patients (Chen et al.,...
effects by hyperglycemic correction (Molinuevo 2015). An epidemiological study suggested that MET inhibits mTOR-dependent translation initiation in breast cancer cells (Dowling et al., 2015). Simultaneously, other studies showed that MET has potential antitumor activity against lung, breast, and colon, pancreatic, prostate, and ovarian cancers (Zheng et al., 2012; Zaidi et al., 2019).

**Metformin enhances probiotics**

Probiotics are living microorganisms that play an essential role in health and disease. They improve the immune system and decrease blood glucose via improving inflammation and preventing β-cells destruction. Furthermore, probiotics may have beneficial effects on glycemic control and lipid profiles in T2DM patients (Bayat et al., 2016). MET showed an impact on some microorganisms of human gut microbiota by influencing folate production and, consequently, inhibiting the growth of some types of bacteria (Olgun, 2017). People with diabetes administrated with MET showed alterations in their microbiota with an abundance of lactobacilli and bifidobacteria, and these species could contribute to the antidiabetic effect (Wu et al., 2017). A previous clinical trial found that combinatorial treatment with probiotics and MET improves liver function better than MET alone in non-alcoholic steatohepatitis patients (Shavakhi et al., 2013). Several studies on rodents and humans suggest that gut microbial changes might contribute to the antidiabetic effect of MET (Forslund et al., 2015; De la Cuesta-Zuluaga et al., 2017).

**Metformin and Bone Health**

MET does not affect glucose levels in non-diabetic individuals, and this represents the idea of using MET as adjuvant therapy, especially in bone disorders. MET has a beneficial impact on bone health by controlling glucose levels that result in enhanced bone turnover, which leads to an imbalance of osteoblast/osteoclast activity (Stage et al., 2018). Patients with T2DM have reported lower biochemical bone turnover markers (Manavalan et al., 2012). MET has been shown to shift the progenitor cells into osteoblasts and showed direct osteogenic effects on bone through AMPK and Runx-related transcription factor 2 (Runx2) and indirect effects by hyperglycemic correction (Molinuevo et al., 2010). A previous study has reported that AMPK promotes MC3T3-E1 cells for osteogenesis via the AMPKGr1- OPN axis pathway (Wang et al., 2016). Another research has suggested that AMPK can suppress RANKL-induced osteoclast formation (Lee et al., 2010). The previous study has shown that MET can be osteogenic in vitro following by activation of AMPK resulting in osteoblastic cells’ differentiation, bone matrix synthesis, and osteoblasts proliferation (Shah et al., 2010). In vitro and in vivo studies showed that MET administration has osteogenic effects and improves bone healing in non-diabetic animals. In diabetic and non-diabetic rats, MET led to an increase in type I collagen synthesis and stimulates the regeneration process in bone lesions (Molinuevo et al., 2010).

Furthermore, MET osteogenic effects were presumably mediated by the induction of nitric oxide synthases (NOS) and extracellular signal-regulated kinase activation (ERK). MET has protective effects against bone loss after ovariectomy in rats and protects bone mass in estrogen deficiency. It has also been reported that MET can increase bone density and mineralization in alveolar bones through osteoblast differentiation in ligature-induced periodontitis in rats (Bak et al., 2010).

**Metformin toxicity**

The common symptoms of MET toxicity include nausea, abdominal pain, vomiting, hypothermia, decreased level of consciousness. One of the most serious side effects of MET treatment is the development of LA due to its blockage of the metabolism of lactate and alanine to pyruvate, which in turn led to the collapse of the cardiovascular system (Wang and Hoyte, 2019). Treatment of MET toxicity is symptomatic and supportive, and there is no antidote available, but LA is commonly treated by sodium bicarbonate or through hemodialysis (Turkcuver et al., 2010). Furthermore, MET impaired vitamin B_{12} uptake in the terminal ileum (Bauman et al., 2000) and folic acid. MET treatment in some cases led to hemolytic anemia, which could be potentiated by immune response or due to glucose-6-phosphate dehydrogenase (6PD) deficiency. Besides its metabolic effect, MET treatment is linked with
a reduction in proteins of coagulation and impaired fibrinolytic activity in T2DM (Ruggiero et al., 2016). Furthermore, MET intoxication led to alterations in specific coagulation parameters. Serious side effects of this drug, such as idiosyncratic hepatotoxicity, were also reported (Miralles-Linares et al., 2012).

CONCLUSION
MET has been widely prescribed to T2DM patients for over 50 years and considered a safe and effective drug when used alone and in combination with other oral antidiabetic agents, with several benefits such as decreased hyperinsulinemia, weight reduction, and improve lipid profile. Recent results also indicated the nephroprotective activity of MET against nephrotoxic agents and demonstrated its effectiveness in reducing the complications associated with nephropathy in chronic kidney diseases. Recently, MET might be used to treat several types of cancer. Different studies indicated that MET is not exclusively used as an antidiabetic drug but also has antioxidant effects, the ability to decrease the complications associated with cardiovascular diseases in diabetics, augment the immune system and probiotics in the gastrointestinal tract.

CONFLICT OF INTEREST
All authors have approved this article and declare no conflicts of interest.

FUNDING
This work did not receive any funds.

References


Mobasher MA, Valverde ÁM. (2014). Signalling pathways involved in paracetamol-induced hepatotoxicity: new insights on the role of protein tyrosine phosphatase 1B. Archives of physiology and biochemistry, 120 (2), 51-63


Hepatocellular Carcinoma with Pre-Existing Diabetes Mellitus Rats. Pathogens, 11;10(1):59.


Egyptian Association for Cancer Research (EACR)
http://eacr.tanta.edu.eg/

EACR is an NGO society that was declared by the Ministry of Social Solidarity (Egypt) No. 1938 in 19/11/2014 based on the initiative of Prof. Mohamed Labib Salem, the current Chairman of EACR. EACR aims primarily to assist researchers, in particular young researchers in the field of cancer research through workshops, seminars and conferences. Its first international annual conference entitled "Anti-Cancer Drug Discovery" was successfully organized in April 2019 (http://acdd.tanta.edu.eg). Additionally, EACR aims to raise the awareness of the society about the importance of scientific research in the field of cancer research in prediction, early diagnosis and treatment of cancer. EACR is also keen to outreach the scientific community with periodicals and news on cancer research including peer-reviewed scientific journals for the publication of cutting-edge research. The official scientific journal of EACR is "International Journal of Cancer and biomedical Research (IJCBR: https://jcbjournals.ekb.eg) was successfully issued in 2017 and has been sponsored by the Egyptian Knowledge Bank (EKB: www.ekb.eg).

EACR Chairman,
Prof. Mohamed Labib Salem, PhD
Professor of Immunology
Faculty of Science, Tanta University, Egypt
GUIDE FOR AUTHORS

Publisher: The International Journal of Cancer and Biomedical Research (IJCBR) is an International and interdisciplinary journal of preclinical and clinical studies in the area of cancer and biomedical research. It is a peer-reviewed journal in English, published quarterly (in March, June, September, and December) by the Egyptian Association for Cancer Research (EACR) in both print and online formats (4 issues making a volume). Special issues or supplements may also be produced from time to time upon agreement with the Editorial Board.

Scope: The main aim of IJCBR is to attract the best research in animal and human biology in health and diseases from across the spectrum of the biomedical sciences at the molecular, cellular, organ, and whole animal levels especially those that are related to cancer research, including causes, prediction, diagnosis, prognosis, and therapy.

Publication Fees: The journal does charge for submission, processing, or publication of manuscripts (2000 LE for Egyptians or 250$ for non-Egyptians; EACR members receive 15% discount on publication). Of them Peer-review fees (300 LE) should be paid on submission (non-refundable). For the fast-track production of the accepted manuscript, another 500 LE is paid.

General specifications for different types of article

- Submitted manuscripts should not have been published previously, except in a limited form (e.g. short communication to a symposium or as part of MSc or PhD theses) and should not be under consideration for publication by other journals.
- All co-authors should agree with the content of the manuscript. Authors must have obtained permission to use any copyrighted material in the manuscript before submission.

IJCBR publishes different types of articles

- Original Article (6000 words with 4 tables and 4 figures, maximum 8 display items): Articles with novel findings are the target of IJCBR. Articles presenting a detailed description of a new technique, comparison of existing methods, meta-analyses with comprehensive and in-depth discussion are considered. Papers in a numbered series are not accepted unless all are submitted at the same time.
- Short communications or case study (3000 words with 4 display items): Short communications present exceptionally exciting, novel or timely contents are considered. They will be peer-reviewed in the same way as research papers. The references are restricted to 15.
- Reviews or systematic review (9000 words with 10 display items): They are invited by the Editorial Board or unsolicited. Review articles have to be contemporary and comprehensive and add information to the knowledge. Sharp critical analyses of novel data or concepts are encouraged. When relevant, a statistical analysis of data and a meta-analysis approach are recommended.
- Opinion papers, letter to the editor or comment to the editor (1500 words with 2 display items): They are submitted by invitation of the Editorial Board. They are short papers, which aim to inform scientists, industry, and the public and policymakers about cutting-edge issues in research or the impact of research. They reflect the opinion of their authors who bear full responsibility of the published paper. The references are restricted to 10.
- Conference/Symposium papers: The journal will consider for publication the results of original work and critical reviews that are presented at conferences/symposia. Symposium organizers who wish to publish bundles of papers from a symposium/conference in IJCBR should first contact the Editor-in-Chief of the IJCBR (EACR@univ.tanta.edu.eg) for agreement. Supplementary material can be proposed and will be made available online. The responsibility for the preparation of a paper in a form suitable for publication lies with the author.
- Thesis: IJCBR can publish the summary and abstract of Master and PhD theses in a special issue.

English: Good quality of written English is required. Spelling may be in British or American English but must be consistent throughout the paper. Care should be exercised in the use of biological terminology that is ill-defined or of local familiarity only. We recommend that authors have their manuscripts checked by an English language native speaker before submission.

Manuscript layout: Manuscripts should be prepared using a standard word processing program and presented in a clear readable format with easily identified sections and headings. The manuscript layout is based on the following directions.

- The main text contains Title, Abstract, Keywords, Introduction, Material and Methods, Results, Discussion, References, Tables, figures.
- The title needs to be concise and informative. Use bold, with an initial capital for the first word only and for words that ordinarily take capitals.
- Short (running) title (max 80 characters including spacing).
- The article text should be typed with double line spacing with wide margins (2.5 cm).
- The lines must be continuously numbered; the pages must also be numbered.
- Font Calibri 12 should be used for the text, and 12 for the tables, figure legends and references.
- The sections should typically be assembled in the following order:
- Title page contains title, authors’ names, full affiliations, acknowledgements and the corresponding author’s contacts and Short title.

Abstract (max 250 words, single paragraph): The abstract should be complete and understandable without citation, references, table, or figure. Use structured abstract: Background, Aim, Materials & Methods, Results and Conclusion. The context and the rationale of the study are presented succinctly to support the objectives. The experimental methods and main results are summarized but should not be overburdened by numerical values or probability values. The abstract ends with a short and clear conclusion.
Keywords: Up to five short and specific keywords should complement the title with respect to indicating the subject of the paper in alphabetic order.

Introduction: The introduction briefly outlines the context of the work, presents the current issues that the authors are addressing and the rationale to support the objectives, and clearly defines the objectives.

Material and methods: Material and methods should be described in sufficient details so that others can repeat the experiment. Reference to previously published work may be used to give methodological details, provided that said publications are readily accessible and in English. The code of ethics should be followed for all experiments use animals or human samples.

Statistical analysis of results: The statistical design and the models of statistical analysis must be described, as well as each of the statistical methods used. Sufficient statistical details must be given to allow replication of the statistical analysis. The experimental unit should be defined (e.g., individual or group of animals).

Results: Data are presented as tables and figures. Brief description of the results for each table and figure should be presented. Unpublished data can be mentioned when necessary.

Discussion: Should be separate from the Results section and should focus only on intra- and inter-data discussion (the data in the results section) as well as with the relative data in the literature. Don't repeat information already presented in the Introduction section. Start the first paragraph in the Discussion with a paragraph stating the rationale behind the study, the objectives, and the main findings. End Discussion with a short conclusion.

Acknowledgements: In this section, the authors may acknowledge (briefly) their support staff.

Conflict of interest: All papers with a potential conflict of interest must include a description/explanation in a separate heading.

Funding details: The authors should state the source of findings of the study (with research funder and/or grant number). If no fund, the authors should state that the study is self-funded.

References
Citation of references: In the text, references should be cited by the author(s) surname(s) and the year of publication (e.g. Salem, 2020). References with two authors should be cited with both surnames (e.g. Salem and Meshref, 2021). References with three or more authors should be cited with the first author followed by et al. (in italics; e.g. Salem et al., 2021). Names of organizations used as authors (e.g. Food and Drug Administration) should be written out in full in the list of references and on the first mention in the text. Subsequent mentions may be abbreviated (e.g. FDA).

- List of references. Literature cited should be listed in alphabetical order by authors' names. It is the author's responsibility to ensure that all references are correct. All authors should be written and so the full journal name.
- References from journal articles are formatted in APA as this example: Al-Amoudi WM (2018). Toxic effects of Lambda-cyhalothrin on the rat thyroid. Involvement of oxidative stress and ameliorative effect of ginger extract. Toxicology Reports, 5: 728-736.
- References from books or official reports are formatted as this example. Kebreab E, Dijkstra ANM, Bannink A, Gerrits WJJ, & France J (2006). Nutrient digestion and utilization in farm animals. CABI Publishing. Wallingford, UK.

Tables: The data should be presented in tables or in graphs, not both.
- Each table should be placed on a separate page at the end of the main text.
- Tables are numbered consecutively using Arabic numbering. They are referred to as Table 1, Table 2, etc., with capital ‘T’, no italics
- Each table has its explanatory caption. The caption is sufficient to permit the table to be understood without reference to the text.
- Abbreviations used in tables/figures have to be defined either as footnotes or in the caption.

Figures
- Package the figures in a single PowerPoint file. Each figure in a separate slide.
- Figure size should be readable in a width of approximately 8-175 mm (i.e. the maximum size of printing over two columns).
- Ensure that the font size is large enough to be readable at the final print size, use Calibri font to ensure that they are consistent throughout the figures.
- The figures should preferably be provided as TIFF or EPS files.
- The resolutions of figures must be at least 300 dpi.
- Preparation of images for a manuscript: For guidance, we refer to the Journal of Cell Biology’s instructions to authors (http://jcb.rupress.org/site/misc/fiora.xhtml#image_aquisition).
- If a cropped image is included in the main text of a paper (e.g. a few lanes of a gel), display the full original image, including the appropriate controls, the molecular size ladder and/or the scale as relevant, as a single figure in a Supplementary Material file to facilitate peer-review and for subsequent online publication.
- Supplementary material is submitted along with the main manuscript in a separate file and identified at uploading as “Supplementary File – for Online Publication Only” The title of the article is included at the top of the supplementary material.

Corresponding author’s guidelines: Upon acceptance the corresponding author is required to send his/her recent formal photo to be attached to the front page of the article.